menu search

Lantheus: fast-growing radiotherapeutics specialist can benefit from lilly's point biopharma takeover

Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product <...

October 12, 2023, 4:35 pm

Lantheus: not quite ready to take the plunge

Radiopharmacy is expected to experience exponential growth over the next decade. Radiopharmaceutical-based therapies offer more targeted and specific ...

August 30, 2023, 8:20 am

Lantheus: pylarify and definity driving strong growth

Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The...

June 18, 2023, 3:54 am

Lantheus announces presentations featuring pylarify ai™ at the 2023 society for nuclear medicine and molecular imaging (snmmi) annual meeting

BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outc...

June 12, 2023, 12:30 pm

Lantheus: managing a winner

Lantheus Holdings reported a strong beat on their fourth-quarter and full-year 2021 earnings. pylarify ...

April 7, 2022, 1:29 pm


Search within

Pages Search Results: